Avenue Therapeuticsincis A Specialty Pharmaceutical Company Based In Bay Harbor Islandsfloridafounded In 2015 As A Subsidiary Of Fortress Biotechinc The Company Focuses On Developing And Commercializing Therapies For Neurologic Diseasesavenue Therapeutics Is Committed To Delivering Impactful Treatments That Aim To Improve Patient Outcomes The Company Is Currently Advancing Several Key Assetsincluding Aj201A First In Class Treatment In Clinical Trials For Spinal And Bulbar Muscular Atrophyand Baer 101An Oral Small Molecule Designed For Cns Diseases Such As Epilepsy And Panic Disordersadditionallyavenue Therapeutics Is Developing Iv Tramadolwhich Is In Phase 3 Clinical Development For Managing Moderate To Moderately Severe Pain In Adults Avenue Therapeutics Is Led By Dralexandra Macleanthe Chief Executive Officeralong With A Team Of Experienced Executivesthe Company Is Publicly Traded On The Otc Markets Under The Ticker Symbol Atxi
